Trial Profile

A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment With Atezolizumab or Placebo in Combination With Platinum-Based Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 22 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Acronyms IMpower030
Sponsors Roche

20 Nov 2024 Planned End Date changed from 19 Jan 2025 to 31 Dec 2025.
20 Nov 2024 Planned primary completion date changed from 19 Jan 2025 to 31 Dec 2025.
06 Apr 2023 Planned End Date changed from 20 Nov 2024 to 19 Jan 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com